Skip to content

Glossary · GHRH analog

Tesamorelin

Also known as: Egrifta · TH9507 · تيسامورلين · Tesamorelina

Class
GHRH analog
Half-life
~30 minutes

Mechanism

Tesamorelin is a synthetic analogue of the full 44-amino-acid human growth hormone-releasing hormone, with a trans-3-hexenoyl group added at the N-terminus. The modification increases resistance to DPP-4 degradation. It acts at pituitary GHRH receptors and stimulates pulsatile release of endogenous growth hormone, which raises IGF-1 concentrations. In clinical studies in HIV-associated lipodystrophy, it reduced visceral adipose tissue without significant change in subcutaneous fat.

Research areas

  • GHRH-receptor pharmacology.
  • Visceral adipose tissue and liver-fat research.
  • GH/IGF-1 axis physiology.

Regulatory status

Tesamorelin is the active substance of an FDA-approved medicine (Egrifta, approved in 2010) for a specific indication in HIV-associated lipodystrophy. The material supplied here is a research reagent and is not that medicinal product. GHRH analogues, including tesamorelin, are listed on the WADA Prohibited List under S2.

Storage and stability

Use the storage instructions for the format supplied. Check the product listing and label; not every compound is available in every format.

  • Peptide vial — Store the lyophilized powder at −20°C. Keep dry and protected from light. After reconstitution, follow the product label’s storage and expiry instructions.
  • Dual-chamber cartridges — Keep refrigerated at 2–8°C, including before activation. The peptide powder and included BAC water remain separate until activation. Follow the cartridge label’s storage and expiry instructions.
  • Multi-dose pen — Keep refrigerated at 2–8°C continuously. The approximate stability window is 30–45 days from the date mixed, depending on the peptide. Follow the product-specific expiry on the label.
  • BAC water — Keep bacteriostatic water refrigerated at 2–8°C. Follow the storage, expiry and discard instructions on the product label.
  • Nasal spray — Store the nasal spray at room temperature. Follow the storage and expiry instructions on the product label.

Related research

Frequently asked

About Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic analogue of the full 44-amino-acid human growth hormone-releasing hormone, with a trans-3-hexenoyl group added at the N-terminus. The modification increases resistance to DPP-4 degradation.

What is the half-life of Tesamorelin?

The reported half-life of Tesamorelin is ~30 minutes. Half-life figures come from published pharmacokinetic studies and vary with the experimental model and formulation.

What class of compound is Tesamorelin?

Tesamorelin is classified as: GHRH analog. In the literature it is also referred to as Egrifta / TH9507.

In which research areas is Tesamorelin studied?

Published research on Tesamorelin includes: GHRH-receptor pharmacology; Visceral adipose tissue and liver-fat research; GH/IGF-1 axis physiology.

What is the regulatory status of Tesamorelin?

Tesamorelin is the active substance of an FDA-approved medicine (Egrifta, approved in 2010) for a specific indication in HIV-associated lipodystrophy. The material supplied here is a research reagent and is not that medicinal product.

Glossary entries describe research pharmacology for in-vitro and laboratory contexts only.